跳至主要内容
临床试验/NCT01995604
NCT01995604撤回不适用

A Single Center, Double Blinded, Placebo Controlled, Randomized, Split Face Study to Evaluate the Efficacy of dHACM (Dehydrated Human Amnion Chorion Membrane) for Recovery After Fractionated Ablative CO2 Laser Resurfacing of the Face

MiMedx Group, Inc.1 个研究点 分布在 1 个国家开始时间: 2013年9月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
撤回
试验地点
1
主要终点
The time to healing for both groups will be assessed as defined by appearance and 100% epithelialization.

研究概览

简要总结

The purpose of this study is to evaluate the efficacy of dHACM (Dehydrated Human Amnion Chorion Membrane) for reducing time to healing when used in post-laser recovery following ActiveFX™ and DeepFx™ fractionated ablative CO2 laser resurfacing of the face.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Male or female subjects in good general health greater than 18 years of age
  • •Must be willing to agree to all terms of the protocol and provide a completed and signed informed consent, HIPAA and photography release forms
  • •Subjects planning to undergo fractionated ablative CO2 laser resurfacing to the full face
  • •Subject of either Fitzpatrick Skin Types I, II or III
  • •For female subjects of childbearing potential, they must have had a regular menstrual cycle prior to study entry and is willing to use an acceptable form of birth control during the entire course of the study. All systemic birth control measures must be in consistent use at least 30 days prior to entry into the study. A female is considered NOT to be of childbearing potential if she is postmenopausal for at least one (1) year, without a uterus and/or both ovaries, or has had a bilateral tubal ligation. Acceptable methods of birth control are: oral contraceptives, contraceptive patches/rings/implants Norplant, Depo-Provera, double-barrier methods (e.g. condoms and spermicide), abstinence and vasectomies of the partner.
  • •Negative urine pregnancy test results at the time of study entry for females of childbearing potential, if applicable
  • •Must be willing to comply with study instructions and complete the entire course of the study

排除标准

  • •Any uncontrolled systemic disease that is not yet stabilized for at least one (1) year
  • •A significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would interfere with the objectives of the study
  • •Recently excessive exposure to sunlight or artificial UV light (e.g.: use of tanning beds/booths and/or sunbathing) or expectations of tanning during the time of the study or has used self-tanner within 7 days of study entry
  • •History of or the presence of any skin condition/disease that might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema, psoriasis, seborrheic dermatitis)
  • •Active bacterial, fungal, or viral infection
  • •History of Herpes Simplex Virus to the facial and/or perioral areas
  • •Known allergies or sensitivities to benzocaine, lidocaine, tetracaine, PABA (para-aminobenzoic acid), or other local anesthetics of the amide or ester family
  • •Known allergies to gentamicin and/or streptomycin
  • •Receiving any topical products containing alpha-hydroxy acids, salicylic acid, and Vitamins C or E (including derivatives of Vitamins C or E) on the face within 14 days prior to or during the study period, other than the ingredients of the study products
  • •Receiving and/or has had a microdermabrasion (light or medium skin peel) treatment on their face within 30 days prior to or during the study period
  • •Using any topical tretinoin product or derivative on their face within 12 weeks prior to or during the study period
  • •Receiving a chemical peel, any systemic steroids, a non-ablative laser, light or radio frequency treatment and/or has had a Dermabrasion (deep skin peel) or ablative laser treatments on their face must have discontinued the drug/treatment and/or had the procedure at least 3 months prior to entering the study
  • •History of keloids or hypertrophic scars
  • •Use of systemic retinoids, prescription or over-the-counter grade within the past year
  • •A female subject who is pregnant, nursing an infant or planning a pregnancy during the study
  • •Current participation or completed participation of a clinical research study for an investigational drug or device within 30 days prior to the start of this study

研究组 & 干预措施

dHACM

Experimental

UltraPulse laser therapy with application of dHACM

干预措施: Application of dHACM (Other)

Sterile 0.9% Saline Solution

Placebo Comparator

UltraPulse laser therapy with application of Sterile 0.9% Saline Solution

干预措施: Application of Sterile 0.9% Saline Solution (Other)

结局指标

主要结局

The time to healing for both groups will be assessed as defined by appearance and 100% epithelialization.

时间窗: Day 30

次要结局

  • Erythema, edema, crusting, and exudate will be compared between both groups.(30 Days)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验